{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-073264","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.488499+00:00","generated_at":"2026-06-25T00:04:08.207391+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Liquidia appoints Dr. Rajeev Saggar as CMO, succeeding Dr. Tushar Shah","bullets":["Dr. Tushar Shah terminated as CMO effective June 15, 2022; severance agreement being finalized.","Dr. Rajeev Saggar appointed CMO effective July 18, 2022; previously VP Clinical Development at Theravance Biopharma.","Dr. Saggar receives $475k base salary, 40% target bonus, $50k sign-on bonus, and equity grants (200k option + RSUs worth $350k).","Dr. Saggar has over 20 years pulmonology experience and served as PI in pivotal INSPIRE study of YUTREPIA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-073264","json":"https://secwatch.observer/filing/0001104659-22-073264.json","markdown":"https://secwatch.observer/filing/0001104659-22-073264.md","text":"https://secwatch.observer/filing/0001104659-22-073264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922073264/0001104659-22-073264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922073264/tm2219020d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:04:08.207391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a63444db1","claim":"Tushar Shah was terminated as Chief Medical Officer at Liquidia Corp.","evidence_excerpt":"Effective June 15, 2022, Tushar Shah, M.D.’s employment with Liquidia Corporation, a Delaware corporation (the “Company”) as the Company’s Chief Medical Officer terminated.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465922073264/0001104659-22-073264-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}